StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Goldman Sachs on Eli Lilly (LLY): 'see the stock weakness as an overreaction'
May 4, 2026 9:27 AM
Goldman Sachs analyst Asad Haider reiterated a Buy rating and $1,283.00 price target on Eli Lilly (NYSE: LLY).The analyst comments ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Hot Comments
Next Articles
RBC Capital on Eli Lilly (LLY): 'we think the sell-off is overdone'
May 4, 2026 10:26 AM
Guggenheim on Cabaletta Bio (CABA): 'compelling evidence that CAR-T activity can be achieved without preconditioning'
May 4, 2026 9:20 AM
Bernstein: We're buyers of weakness in LLY
May 4, 2026 9:15 AM
Eli Lilly (LLY) PT Raised to $1,400 at Barclays, 'A remarkably strong quarter...and LLY's only just getting started'
May 4, 2026 8:58 AM
Wolfe Research Defending Eli Lilly (LLY) Amid 1.53% Drop: 'Faers For Foundayo Are Unfounded'
May 4, 2026 8:57 AM
Why Eli Lilly stock is down 3% today: FDA adverse event data explained
May 4, 2026 8:44 AM
Form SCHEDULE 13G ELI LILLY & Co Filed by: VANGUARD CAPITAL MANAGEMENT LLC
May 1, 2026 11:53 AM
Eli Lilly (LLY) PT Lowered to $1,133 at BofA Securities
May 1, 2026 10:53 AM
Eli Lilly (LLY) PT Raised to $1,344 at Morgan Stanley
May 1, 2026 9:13 AM
Novo Nordisk rebrands diabetes tablet as Ozempic in US
May 1, 2026 8:34 AM
Eli Lilly (LLY) PT Raised to $1,230 at Cantor Fitzgerald
May 1, 2026 7:13 AM
Eli Lilly's oral weight loss drug sees over 5,600 prescriptions in third week
May 1, 2026 7:03 AM
Lilly's Strong GLP-1 Results Signal Robust Market Growth for Novo Nordisk says Barclays
April 30, 2026 4:19 PM
Form 10-Q ELI LILLY & Co For: Mar 31
April 30, 2026 11:26 AM
FDA proposes to exclude semaglutide, tirzepatide from compounding list
April 30, 2026 9:23 AM
Lilly surges on earnings beat and raised guidance
April 30, 2026 7:21 AM
Form 8-K ELI LILLY & Co For: Apr 30
April 30, 2026 7:03 AM
Eli Lilly & Co. (LLY) Tops Q1 EPS by $1.58, Beats on Revenue; Offers Strong Guidance
April 30, 2026 6:48 AM
Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines
April 30, 2026 6:45 AM
Eli Lilly & Co. (LLY) call put ratio 1.1 calls to 1 put into quarter results
April 30, 2026 3:28 AM
Eli Lilly Q1 earnings preview: analysts eye outlook for obesity drugs
April 30, 2026 2:00 AM
